Recent warnings from the Royal Osteoporosis Society highlight a potential link between GLP-1 weight-loss drugs and osteoporosis. Research indicates that users might lose up to 40% of their weight from muscle and bone mass. This loss can lead to a higher risk of fractures and reduced mobility. With over half a million users in the UK, experts stress the importance of discussing these risks with healthcare professionals before starting treatment, especially for individuals vulnerable to osteoporosis, such as post-menopausal women.
Losing muscle can impair strength and joint stability, while reduced bone density raises the risk of osteoporosis - a condition that can cause brittle bones.
Any drug that reduces muscle mass and bone density is a bad idea for people who are frail and those vulnerable to fractures with osteoporosis.
Bone and muscle health is key to preventing the risk of falling and fractures which can lead to premature death or else have a devastating effect on people's ability to live independently.
It's essential that fat jabs are prescribed appropriately after a discussion with a doctor.
Collection
[
|
...
]